Clinical trials: Squamous Non-Small Cell Lung Cancer
Carcinoma
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
The main purpose of this observational study with Docetaxel is to determine the number of treatment cycles and the quantity of Doce onkovis needed therefore under the special circumstance of ambulant chemotherapy.
- Trial name
- NCT01614002
- Where
- 23 sites in Germany
- Volunteers
- 371 people
- Sponsor
- Onkovis GmbH
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Carcinoma, Squamous Cell Carcinoma of Head and Neck
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
In this study, participants with different types of advanced solid tumors who failed standard treatments will be treated with XNW5004 in combination with KEYTRUDA® (pembrolizumab) .
- Conditions
- Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Prostate Cancer
- Trial name
- NCT06022757
- Testing
- XNW5004, KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Evopoint Biosciences Inc.
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
This is a randomized, open-label, multi-center, global phase II/III clinical study to evaluate the efficacy and safety of HLX43 monotherapy or HLX43 in combination with HLX07 vs.
- Trial name
- NCT07459751
- Testing
- HLX43, HLX43+HLX07, Docetaxel
- Where
- China
- Volunteers
- 706 people
- Sponsor
- Shanghai Henlius Biotech
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma
- Trial name
- NCT06799065
- Testing
- ATX-295, ATX-295 and bevacizumab (or biosimilar)
- Where
- 11 sites in United States
- Volunteers
- 218 people
- Sponsor
- Accent Therapeutics
Urothelial Carcinoma, Triple Negative Breast Cancer
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, dose-escalation and expansion study designed to investigate SBT6290 administered alone and in combination with pembrolizumab in advanced solid tumors associated with Nectin-4…
- Conditions
- Urothelial Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT05234606
- Testing
- SBT6290, pembrolizumab
- Sponsor
- Silverback Therapeutics
Non-Small-Cell Lung Carcinoma, Colorectal Cancer
A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer
In study, liquid biopsy samples will be obtained from non-small cell lung cancer (NSCLC) including Squamous cell carcinoma, Adenocarcinoma and large cell carcinoma, colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma…
- Conditions
- Non-Small-Cell Lung Carcinoma, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05708599
- Testing
- Liquid biopsy
- Where
- Germany
- Volunteers
- 102 people
- Sponsor
- Boehringer Ingelheim
Non-Squamous Non-Small Cell Lung Cancer
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
The anti-tumor activity of anti-PD-1 therapy and VEGF inhibitor in TKI-resistant EGFR-mutated non-squamous NSCLC Chinese patients will be investigated in this clinical trial.
- Trial name
- NCT03802240
- Testing
- Sintilimab, IBI305, Pemetrexed
- Where
- China
- Volunteers
- 492 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Lung Cancer, Non-small Cell Lung Cancer
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients
In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference product EU-licensed Avastin®. The aim of the study is to demonstrate equivalence of HD204 and EU-licensed Avastin® in terms of efficacy…
- Trial name
- NCT03390686
- Testing
- Bevacizumab, HD204, Carboplatin
- Where
- 18 sites in Belarus, Bulgaria and 15 more
- Volunteers
- 650 people
- Sponsor
- Prestige Biopharma Limited
Non Small Cell Lung Cancer, Hepatocellular Carcinoma
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
This is a Phase 1, open-label, dose escalation and expansion study of MT-8421 (an Engineered Toxin Body (ETB)) as monotherapy and in combination with nivolumab in patients with selected advanced solid cancer types.
- Conditions
- Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT06034860
- Testing
- MT-8421, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Molecular Templates, Inc.
Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
This study will explore the correlation of biomarkers with response rate, and the overall efficacy and safety, of Avastin in combination with carboplatin-based chemotherapy in patients with advanced or recurrent non-squamous…
- Trial name
- NCT00700180
- Testing
- bevacizumab [Avastin], Carboplatin-based chemotherapy
- Where
- 59 sites in Australia, Belgium and 14 more
- Volunteers
- 303 people
- Sponsor
- Hoffmann-La Roche
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05983133
- Testing
- PF-08046052
- Where
- 24 sites in United States, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Advanced Cancer
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with…
- Trial name
- NCT02554812
- Testing
- Avelumab, Utomilumab, PF-04518600
- Where
- 88 sites in United States, Australia and 6 more
- Volunteers
- 409 people
- Sponsor
- Pfizer
Non-Small-Cell Lung Cancer
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
Efficacy and safety evaluation of PLB1004 in patients with locally advanced/metastatic non-squamous NSCLCharboring EGFR exon 20 insertion.
- Trial name
- KANNON-2 (NCT06281964)
- Testing
- PLB1004, Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab
- Where
- China
- Volunteers
- 327 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
NSCLC
A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
Fruquintinib/Placebo 5 mg, QD, orally administered under fasting conditions for 3 consecutive weeks followed by one-week off to evaluate the survival benefit of patients with advanced non-squamous NSCLC treated with Fruquintinib.
- Trial name
- FALUCA (NCT02691299)
- Testing
- Fruquintinib
- Where
- 11 sites in China
- Volunteers
- 527 people
- Sponsor
- Hutchison Medipharma Limited
Non-squamous, Non-Small Cell Lung Cancer
The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer
This study aims to observe the sequential strategy with afatinib as first-line treatment and to find the optimal treatment strategy for long-term chemotherapy-free regimens in Chinese patients with EGFR-mutated advanced NSCLC.
- Trial name
- NCT04206787
- Testing
- Afatinib
- Where
- 10 sites in China
- Volunteers
- 72 people
- Sponsor
- Boehringer Ingelheim
Cancer, Tumor, Solid
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805…
- Conditions
- Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer
- Trial name
- NCT05094804
- Testing
- OR2805, Cemiplimab, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 172 people
- Sponsor
- OncoResponse, Inc.
Non-Squamous Non-Small Cell Lung Cancer
A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer
This is a multicentre, randomized, double-blind, parallel-controlled integrated phase I/III clinical study to evaluate the similarity in efficacy, safety, PK profile, and immunogenicity of HLX17 vs.
- Trial name
- NCT06847334
- Testing
- HLX17, US-sourced Keytruda®, EU-sourced Keytruda®
- Volunteers
- 772 people
- Sponsor
- Shanghai Henlius Biotech
Non-squamous Non-small Cell Lung Cancer
Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
This is an open label single group, Phase 2, 1-arm study for treatment to evaluate efficacy, safety, and Pharmacokinetic (PK) of tusamitamab ravtansine in nonsquamous non-small-cell-lung-cancer (NSQ NSCLC) participants with…
- Trial name
- CARMEN-LC06 (NCT05245071)
- Testing
- Tusamitamab ravtansine
- Where
- 35 sites in United States, Belgium and 5 more
- Volunteers
- 22 people
- Sponsor
- Sanofi
Non-Small Cell Lung Cancer
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
To compare the efficacy and safety of ceritinib with standard first-line chemotherapy (pemetrexed plus cisplatin or carboplatin) in patients with stage IIIB (not candidates for definitive multimodality therapy) or stage IV…
- Trial name
- NCT01828099
- Testing
- Ceritinib, Pemetrexed, Cisplatin
- Where
- 167 sites in Argentina, Australia and 27 more
- Volunteers
- 376 people
- Sponsor
- Novartis Pharmaceuticals